Insider · CIK 0001584759

Heyman Richard A.

Reports to the SEC for 10 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001584759

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-01	ORICOric Pharmaceuticals, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−3,500 sh	—	—	26,700
2026-10-01	ORICOric Pharmaceuticals, Inc.S Sale	Director	SSale	−3,200 sh	$12.91	−$41.3K	203,472
2026-10-01	ORICOric Pharmaceuticals, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,500 sh	$1.60	+$5,600	41,800
2026-10-01	ORICOric Pharmaceuticals, Inc.S Sale	Director	SSale	−3,500 sh	$12.91	−$45.2K	38,300
2026-07-24	ORICOric Pharmaceuticals, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−3,500 sh	—	—	30,200
2026-07-24	ORICOric Pharmaceuticals, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,500 sh	$1.60	+$5,600	45,300
2026-07-24	ORICOric Pharmaceuticals, Inc.S Sale	Director	SSale	−6,100 sh	$12.02	−$73.3K	206,672
2026-07-24	ORICOric Pharmaceuticals, Inc.S Sale	Director	SSale	−7,000 sh	$12.02	−$84.1K	38,300
2026-07-06	ORICOric Pharmaceuticals, Inc.S Sale	Director	SSale	−300 sh	$12.00	−$3,600	212,772
2026-02-17	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−1,230 sh	$26.18	−$32.2K	22,647
2026-02-12	ELVNEnliven Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+19.2K sh	—	—	19,234
2026-01-20	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−718 sh	$26.96	−$19.4K	23,877
2026-01-20	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−512 sh	$26.46	−$13.5K	24,595
2026-01-16	ORICOric Pharmaceuticals, Inc.S Sale	Director	SSale	−3,200 sh	$12.00	−$38.4K	213,072
2026-01-16	ORICOric Pharmaceuticals, Inc.S Sale	Director	SSale	−3,500 sh	$12.00	−$42K	41,800
2026-01-09	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−4,285 sh	$25.00	−$107K	25,107
2026-01-08	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−8,015 sh	$25.04	−$201K	29,392
2026-01-08	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−1,620 sh	$25.00	−$40.5K	25,545
2026-01-02	ORICOric Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+40K sh	—	—	40,000
2025-10-03	ORICOric Pharmaceuticals, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−1,447 sh	—	—	52,253
2025-10-03	ORICOric Pharmaceuticals, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−13.2K sh	—	—	33,700
2025-10-03	ORICOric Pharmaceuticals, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+31.4K sh	$1.60	+$50.2K	43,853
2025-10-03	ORICOric Pharmaceuticals, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−18.1K sh	—	—	0
2025-10-03	ORICOric Pharmaceuticals, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+1,447 sh	$3.75	+$5,426.25	45,300
2025-06-05	PMVPPMV Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+33.5K sh	—	—	33,500
2025-02-06	ELVNEnliven Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+23K sh	—	—	23,014
2025-01-02	ORICOric Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+35K sh	—	—	35,000
2024-10-18	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−753 sh	$30.00	−$22.6K	27,165
2024-10-18	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−817 sh	$30.00	−$24.5K	123,673
2024-10-15	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−1,270 sh	$27.67	−$35.1K	124,490
2024-10-04	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−2,825 sh	$27.51	−$77.7K	125,760
2024-10-01	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−518 sh	$27.54	−$14.3K	128,585
2024-09-16	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−1,270 sh	$22.41	−$28.5K	129,103
2024-08-15	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−620 sh	$23.70	−$14.7K	130,373
2024-08-15	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−650 sh	$22.82	−$14.8K	130,993
2024-07-31	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−1,702 sh	$27.51	−$46.8K	131,643
2024-07-31	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−649 sh	$27.50	−$17.8K	27,918
2024-07-15	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−1,270 sh	$24.80	−$31.5K	133,345
2024-06-17	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−1,270 sh	$21.48	−$27.3K	134,615
2024-06-12	ORICOric Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+25.6K sh	—	—	25,600
2024-06-06	PMVPPMV Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+67.5K sh	—	—	67,500
2024-05-16	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−1,270 sh	$23.74	−$30.1K	135,885
2024-04-15	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−80 sh	$20.68	−$1,654.184	137,155
2024-04-15	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−1,190 sh	$19.94	−$23.7K	137,235
2024-04-11	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−5,045 sh	$25.03	−$126K	138.425
2024-04-11	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−649 sh	$25.00	−$16.2K	28,567
2024-03-19	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−1,270 sh	$14.50	−$18.4K	143,470
2024-02-26	RayzeBio, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−367K sh	$62.50	−$23M	0
2024-02-15	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−1,270 sh	$17.42	−$22.1K	144,740
2024-02-13	ELVNEnliven Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+29.2K sh	—	—	29,205

Recent filings

Accepted (ET)
Oct 24
Heyman Richard A.0001584759-26-000017
SEC(opens sec.gov)
Jul 284
Heyman Richard A.0001584759-26-000015
SEC(opens sec.gov)
Jul 84
Heyman Richard A.0001584759-26-000012
SEC(opens sec.gov)
Feb 194
Heyman Richard A.0001584759-26-000009
SEC(opens sec.gov)
Feb 174
Heyman Richard A.0001584759-26-000008
SEC(opens sec.gov)
Jan 224
Heyman Richard A.0001584759-26-000007
SEC(opens sec.gov)
Jan 204
Heyman Richard A.0001584759-26-000006
SEC(opens sec.gov)
Jan 124
Heyman Richard A.0001584759-26-000004
SEC(opens sec.gov)
Jan 64
Heyman Richard A.0001584759-26-000003
SEC(opens sec.gov)
Oct 34
Heyman Richard A.0001584759-25-000004
SEC(opens sec.gov)

Companies

Address

C/O ORIC PHARMACEUTICALS, INC. 240 E. GRAND AVE., 2ND FLOOR

SOUTH SAN FRANCISCO, CA, 94080